Protillion Biosciences
- Company typePrivate
- Founded2019
- HeadquartersBurlingame, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Protillion Biosciences firmographics
Firmographics- Name
- Protillion Biosciences
- Legal name
- Protillion Biosciences, Inc.
- Website
- https://protillion.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Protillion Biosciences industry classification
Industry- Product category
- Biologics Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Protillion Biosciences is headquartered
LocationHeadquarters
- HQ city
- Burlingame
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Protillion Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Partnership and Milestone Payments: Protillion receives undisclosed upfront payments plus research, development, and commercial milestone payments from pharmaceutical partners. The Merck agreement includes potential milestone payments of up to $510 million for successful development of multiple therapies.
- Drug Discovery Services: Commercial drug discovery partnerships where the company's platform enables partners to perform quantitative analysis on complete protein libraries, producing actionable insights in days rather than months.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Protillion Biosciences product offering
Product offeringCore offering
Protillion Biosciences operates the Prot-MaP (Protein interaction Mapping byseq-based Analysis using Protein display) platform, a megascale data generation system that combines on-chip protein analysis with AI/machine learning to characterize millions of antibody variants per run at amino acid resolution. The platform enables rapid discovery and optimization of therapeutic antibodies and biologics with sophisticated profiles such as pH-dependent sweeping and multi-target specificity. The company monetizes this capability through multi-target drug discovery collaborations and license agreements with global pharmaceutical partners, including a Merck agreement with potential milestone payments of up to $510 million.
Product overview
Protillion Biosciences offers a unified platform centered on its proprietary Prot-MaP technology, a megascale data generation platform that delivers massive training datasets to protein design AI. The platform is supported by high-throughput instrumentation capable of characterizing approximately 1 million antibody variants in a 2-day automated run. The technology combines next-generation sequencing approaches with machine learning to enable quantitative protein analysis at unprecedented scale, facilitating the discovery and optimization of therapeutic antibodies and biologics with sophisticated profiles such as pH-dependent sweeping and multi-target specificity.
Differentiator
Problem solved
Functional benefit
Products and services
- Prot-MaP Megascale Data Generation Platform Prot-MaP is Protillion's proprietary megascale data generation platform purpose-built to deliver massive, just-in-time training sets to protein design AI. It enables quantitative analysis of complete protein libraries at unprecedented throughput, characterizing millions of antibody variants per run with perfect amino acid resolution, and supports a lab-in-the-loop AI workflow for therapeutic antibody discovery and optimization. The platform is sold to enterprise pharmaceutical partners through multi-target discovery collaborations and license agreements.
Quantifiable outcome
- Characterization of approximately 1 million antibody variants in a 2-day automated run
- +1 more outcomes
Companies that use Protillion Biosciences
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Protillion Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Protillion Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Merck & Co.coreProtillion entered into a multi-target drug discovery collaboration and license agreement with Merck. The partnership combines Protillion's AI-powered Prot-MaP platform with Merck's global biopharmaceutical expertise to discover novel therapeutic candidates. Protillion receives an undisclosed upfront payment and is eligible for up to $510 million in research, development, and commercial milestone payments for multiple therapeutic programs. The collaboration aims to identify optimized biologics with sophisticated therapeutic profiles such as pH-dependent sweeping and multi-target specificity.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Protillion Biosciences competitors and assessment
Company assessmentDirect peers
- Generate Biomedicines: AI-driven generative biology company designing novel protein therapeutics using foundation models trained on proprietary data. Most directly comparable to Protillion's AI-enabled biologic discovery platform and pharma partnership GTM.
- BigHat Biosciences: Combines high-throughput wet-lab experimentation with ML to engineer better antibodies. Closely mirrors Protillion's lab-in-the-loop architecture for antibody discovery and optimization.
- Cradle Bio: AI platform for protein design and engineering serving pharma and industrial biotech customers. Competes with Protillion in AI-enabled protein engineering and pharma partnerships.
- Absci: Public AI-driven drug creation company combining generative AI with high-throughput wet-lab validation for antibody discovery. Closely comparable in tech stack and pharma partnership model.
- AbCellera Biologics: Public antibody discovery platform using high-throughput single-cell screening plus AI/ML. Comparable in delivering pharma partnerships with upfront and milestone payments on antibody programs.
Emerging players
- Adaptyv Bio: Early-stage protein engineering platform using high-throughput wet-lab experimentation combined with ML for binder and antibody optimization. Smaller and earlier stage but overlaps on the Prot-MaP thesis.
- Menten AI: AI protein design company building generative models for de novo protein and enzyme engineering. Adjacent technology stack to Protillion but focused on enzyme design rather than antibody libraries.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery company pursuing protein structure and design at scale. Operates with significantly more capital and broader scope, competing for the same pharma AI-discovery partnerships.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company using high-throughput biology plus ML across multiple therapeutic modalities. Broader platform with internal pipeline, but overlaps with Protillion on data-driven drug discovery.
Others
- Denovium (now part of Ginkgo Bioworks): AI protein engineering capability absorbed into Ginkgo Bioworks. Represents the broader AI-protein-design ecosystem where Protillion competes and could be acquired.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Protillion Biosciences social profiles
Digital presenceProtillion Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Protillion Biosciences leadership team
Management profileNumber of profiles
Profiles14 records
Protillion Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Protillion Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Protillion Biosciences
What does Protillion Biosciences do?
Protillion Biosciences operates the Prot-MaP (Protein interaction Mapping byseq-based Analysis using Protein display) platform, a megascale data generation system that combines on-chip protein analysis with AI/machine learning to characterize millions of antibody variants per run at amino acid resolution. The platform enables rapid discovery and optimization of therapeutic antibodies and biologics with sophisticated profiles such as pH-dependent sweeping and multi-target specificity. The company monetizes this capability through multi-target drug discovery collaborations and license agreements with global pharmaceutical partners, including a Merck agreement with potential milestone payments of up to $510 million.
Is Protillion Biosciences a public or private company?
Protillion Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Protillion Biosciences founded?
Protillion Biosciences was founded in 2019. It employs 11 to 50 people.
Where is Protillion Biosciences based?
Protillion Biosciences is headquartered in Burlingame, United States, in the North America region.
How does Protillion Biosciences make money?
Two revenue lines are on record. Partnership and Milestone Payments are the primary driver. The others are drug Discovery Services.
Who are Protillion Biosciences's main competitors?
Direct peers on record are Generate Biomedicines, BigHat Biosciences, Cradle Bio, Absci and AbCellera Biologics. Emerging players are Adaptyv Bio and Menten AI. Broad incumbents are Isomorphic Labs and Recursion Pharmaceuticals. Denovium (now part of Ginkgo Bioworks) is listed as an others.
Does Protillion Biosciences have an API?
No public API is recorded for Protillion Biosciences.
What industry is Protillion Biosciences in?
Protillion Biosciences's product category is Biologics Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.